Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
← catalyst calendarSponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 3
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
102actual
Sites
31
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov within 1 year of the primary completion date.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-05-18 | actual | When the study began enrolling |
| Primary completion | 2025-10-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-13 | actual | The whole study's end, after follow-up |
| First posted | 2018-05-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non Small Cell Lung Cancer
Interventions
- Drug: NAI + Pembrolizumab
- Drug: NAI + Nivolumab + Ipilimumab
- Drug: NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel
- Drug: Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI
- Drug: Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI
- Drug: Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI
- Drug: Carboplatin + Nab-paclitaxel + Atezolizumab + NAI
- Drug: Pembrolizumab
- Drug: Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel
- Drug: Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab
- Drug: Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab
- Drug: Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab
- Drug: Carboplatin and Nab-paclitaxel plus Atezolizumab
- Drug: Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel
Primary outcomes
what the primary-completion date above is the date OFProgression Free Survival (PFS)
measured 24 Months
Change in absolute lymphocyte count (ALC).
measured Significantly Higher ALC Values Over Time Between Experimental & Control Arms Through 27 Weeks
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed